Effect of Evobrutinib on Pharmacokinetics of a Combined Oral Contraceptive
Status:
COMPLETED
Trial end date:
2022-11-25
Target enrollment:
Participant gender:
Summary
The purpose of this study was to assess the effect of M2951 on the pharmacokinetics (PK) of a combined oral contraceptive \[Ethinyl estradiol/Norethisterone (EE/NET)\] in healthy female participants.
* Study Duration: up to 46 days
* Treatment Duration: Days 4 to 17 (14 days treatment with M2951); Days 1 and 15 (2 days treatment with Combined Oral Contraceptive \[COC\])
* Visit Frequency: Participants were resident in the Clinical Research Unit from Day -1 to Day 18.
Phase:
PHASE1
Details
Lead Sponsor:
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany